About Hememics Biotechnologies
Hememics Biotechnologies is a company based in Gaithersburg (United States) founded in 2009 by David Huy Ho and John L Warden. Hememics Biotechnologies has raised $4.6 million across 5 funding rounds from investors including HHS, TEDCO and American Vietnamese Investment Partners. The company has 13 employees as of December 31, 2022. Hememics Biotechnologies offers products and services including HemBox, Hem Chip Reader, and Biochip. Hememics Biotechnologies operates in a competitive market with competitors including DermaSensor, Souzhou Ribo Life Science, Zerigo Health, Cardea Bio and Senzo, among others.
- Headquarter Gaithersburg, United States
- Employees 13 as on 31 Dec, 2022
- Founders David Huy Ho, John L Warden
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hememics Biotechnologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.6 M (USD)
in 5 rounds
-
Latest Funding Round
$2 M (USD), Seed
May 25, 2023
-
Investors
HHS
& 2 more
-
Employee Count
13
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hememics Biotechnologies
Hememics Biotechnologies offers a comprehensive portfolio of products and services, including HemBox, Hem Chip Reader, and Biochip.
Handheld device for rapid detection of substances in various fields
Reader for accurate biochip results in testing applications
Multiplexed chip for simultaneous detection of multiple targets
People of Hememics Biotechnologies
Unlock access to complete
Unlock access to complete
Funding Insights of Hememics Biotechnologies
Hememics Biotechnologies has successfully raised a total of $4.6M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hememics Biotechnologies
Hememics Biotechnologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, TEDCO and American Vietnamese Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund and startup accelerator programs focused on seed and early stage companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Hememics Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hememics Biotechnologies
Investment portfolio details for Hememics Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hememics Biotechnologies
Detailed financials for Hememics Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hememics Biotechnologies Comparisons
Peer comparison for Hememics Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hememics Biotechnologies
Hememics Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermaSensor, Souzhou Ribo Life Science, Zerigo Health, Cardea Bio and Senzo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Handheld diagnostic device for skin cancer lesions is developed.
|
|
| Locked | Locked | Locked |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| Locked | Locked | Locked |
Developer of UVB light therapy devices for monitoring Psoriasis, Vitiligo, and Eczema
|
|
| Locked | Locked | Locked |
Digital graphene biosensors are developed using machine learning.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Next-generation sequencing is provided for microbiology testing applications.
|
Detailed competitors of Hememics Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hememics Biotechnologies
Complete news archive for Hememics Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hememics Biotechnologies
Hememics Biotechnologies was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Hememics Biotechnologies is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John L Warden is the current CEO of Hememics Biotechnologies. They have also founded this company.
Hememics Biotechnologies is a funded company, having raised a total of $4.6M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Hememics Biotechnologies is 13.
Founded in 2009 and headquartered in Gaithersburg, United States, HeMemics Biotechnologies operates in the biotechnology sector focused on biopreservation. Patented HeMeDri technology is utilized to create preservation solutions such as HemSol, which enable storage of mammalian cells and perishable biologics in desiccated or non-desiccated forms at cold or ambient temperatures. Customized stabilization services are provided for proteins, cells, and tissues in dried or non-dried formats to facilitate storage and transport.
Hememics Biotechnologies's top competitors include Nix, DermaSensor and Souzhou Ribo Life Science.
Hememics Biotechnologies offers HemBox, Hem Chip Reader, and Biochip.